
104 KATSIS-1: Randomized Phase 3 Trial Evaluating KAT6 Inhibitor PF-07248144 (prifetrastat) Plus Fulvestrant in HR+HER2− Advanced/Metastatic Breast Cancer After Progression on CDK4/6 Inhibitor-Based Therapy
<a href="https://news.google.com/rss/articles/CBMi2AJBVV95cUxORERzLVpoWnh2bWhDd2JJNkRBSl9CcFV4SkkzYVgwR1pCaVd6V2ktY3pmeVNfak1MT3BRcUczWjNjNEdUcFVZWHVCMDdGelZyS0RBRTZBX2ZyVUQ0el9UeHpyZHdaNHFkWWhYdkUtT3NwZkRtajVNMFdoVDg0ZnlVSXMyZ3BDcjlETUM2RUhZeFBwUmVvREh5TlFQUXlVWTRMYWEyZXVqajFDYjFXbzhfYmFDcE9XeG1PeXctdUdPOWh4aWI1SzdCOFBvc25jdkx4UFNIR3VHdWtfYllIdG8xQk9HN2t3RHF1dGhBdlNfQVpJTHZxLTdIdUhreDFieERpc2JHb1BBUkhlVnpHVzJmOWZ0bk1ZWUFFTy10SXhPNnVkQU1KU2lUb2pRZnBRdVZUdW9HUE5jQWxLd2paUzF3Y3NFYVR0dkd1TEYtdWI4bHNqbEMydVk3Ng?oc=5" target="_blank">104 KATSIS-1: Randomized Phase 3 Trial Evaluating KAT6 Inhibitor PF-07248144 (prifetrastat) Plus Fulvestrant in HR+HER2− Advanced/Metastatic Breast Cancer After Progression on CDK4/6 Inhibitor-Based Therapy</a>&nbsp;&nbsp;<font color="#6f6f6f">CancerNetwork</font>